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Biocompatible in situ gelling hydrogel formulations for intra-articular drug delivery
1. Introduction 3. Synthesis of DIBAC 6. 1H-NMR characterization of DIBAC
• Osteoarthritis (OA) is a progressive disease impacting > 4
million Canadian adults [1]. OA results in the overall
degeneration of the joint which is typically accompanied
by pain and stiffness that can be debilitating [2].
• Currently there are no disease-modifying treatments
available that aim to slow the progression of OA [2].
• An injectable hydrogel formulation developed in our lab
using a free radical crosslinking system has shown
promise for the sustained release of disease-modifying
drugs in the joints.
• Alternative crosslinking mechanisms are needed, that
avoid free radicals to achieve a clinically-translatable
formulation.
• This study focuses on a crosslinking system that uses
copper-free click chemistry [3]. The reaction is based on
the strain-promoted azide-alkyne cycloaddition (SPAAC)
of an azido-endcapped poly(caprolactone-co-lactide)-
poly(ethylene glycol)-poly(caprolactone-co-lactide) (N3-
PCLA-PEG-PCLA-N3) triblock copolymer and a PEG star
polymer with a strained-alkyne end group, such as an
azadibenzocyclooctyne (DIBAC) [3,4].
This biocompatible drug delivery system will be applied to
disease-modifying drugs to treat OA. The drug-loaded
hydrogel will be injected directly into the targeted joint as a
liquid at or below 21oC . The thermoresponsive hydrogel
will gel spontaneously at 37oC under physiological
conditions. The system will achieve a sustained drug
release over a prolonged period.
2. Purpose
4. Synthesis of 4-arm PEG-DIBAC
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7. Conclusions and current work
• Precursors for hydrogel formation were successfully prepared
• Gelation tests are currently being carried out
• The hydrogels will be further characterized through mechanical
tests including syneresis and degradation studies, in vitro
release studies, and cytotoxicity tests.
5-[11,12-Didehydrodibenzo[b,f]azocin-5(6H)-yl]-4-oxobutanoic Acid (DIBAC)
5. Synthesis of azido-endcapped PCLA-PEG-PCLA
